MMJ International Holdings (MMJ), an entrepreneurial cannabis-based research and development venture with operations in the United States and Jamaica recently shared government hearings and what the venture’s principals hope, is a movement to loosen up cannabis laws to encourage medical research. MMJ stands to gain, should that happen. as they seek to initiate clinical trials in Multiple Sclerosis (MS) and Huntington’s Disease (HD) to prove safety and efficacy for patients. But they will need money first, and the cannabis investment climate of late is cold. Possibly helping their cause, according to their press, they have accomplished a number of important milestones—including DEA’s most recent approval for its THC and CBD international shipment to the US for additional development of its plant-derived cannabinoid drug and an FDA “Orphan Drug Designation” award for its proprietary drug formulation. Could this thinly capitalized, boot-strapped, but focused and differentiated venture, rise to higher heights above the rest of the cannabis medical R&D pack?
Government Agencies Acknowledge Inadequate Supply of Cannabis for Study Purposes
The House Energy and Commerce Subcommi...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).